Want to see CNSY full AI Analyst Report?
Top Page
Cerenome
(NASDAQ:CNSY)
Select Model
Select Model
Rating:44Neutral
Price Target:
$3.50
▼(-8.62% Downside)
Action:Reiterated
Date:06/26/26
The score is held down primarily by weak financial performance (very large losses and heavy cash burn) and bearish technicals (price below major moving averages with negative MACD). Corporate events provide a positive offset (Nasdaq compliance restored and FDA Orphan Drug Designation), but valuation is not meaningfully supportive due to negative earnings and no dividend.
Positive Factors
High Gross Margins
Sustained very high gross margins indicate the company’s radiotherapeutic products have favorable unit economics. If clinical programs advance and sales scale, these margins support durable operating leverage and potential profitability despite current fixed R&D costs.
Negative Factors
Negative Cash Flow / High Burn
Persistent, substantial cash burn relative to company scale creates structural funding risk. Continued negative operating and free cash flow means the company must secure external capital to sustain trials, which can delay programs or force unfavorable financing terms.
Read all positive and negative factors
Positive Factors
Negative Factors
High Gross Margins
Sustained very high gross margins indicate the company’s radiotherapeutic products have favorable unit economics. If clinical programs advance and sales scale, these margins support durable operating leverage and potential profitability despite current fixed R&D costs.
Read all positive factors
Cerenome (CNSY) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$25.33M
Dividend YieldN/A
Average Volume (3M)191.43K
Price to Earnings (P/E)―
Beta (1Y)1.36
Revenue Growth-20.95%
EPS Growth91.97%
CountryUS
Employees28
SectorHealthcare
Sector Strength45
IndustryMedical - Pharmaceuticals
Share Statistics
EPS (TTM)-417.08
Shares Outstanding6,883,106
10 Day Avg. Volume153,178
30 Day Avg. Volume191,434
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)9.98
Price to Sales (P/S)7.65
P/FCF Ratio-1.91
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$39.67Price Target Upside935.68% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)-3.98
Revenue Forecast (FY)$6.24M
Cerenome Business Overview & Revenue Model
Company Description
Plus Therapeutics, Inc. is a clinical-stage pharmaceutical company. The firm focuses on the development of chemotherapeutics and radio therapeutics for rare cancers that address unmet medical and market needs. Its products include Rhenium NanoLipo...
How the Company Makes Money
Plus Therapeutics is a clinical-stage company and does not consistently generate product sales like a commercial pharmaceutical company. Its ability to make money is primarily tied to (1) external financing and (2) potential future monetization of...
Cerenome Financial Statement Overview
Summary
Income Statement
24
Negative
Balance Sheet
43
Neutral
Cash Flow
18
Very Negative
| Breakdown |
|---|
Income Statement |
| Total Revenue |
| Gross Profit |
| EBITDA |
| Net Income |
Balance Sheet |
| Total Assets |
| Cash, Cash Equivalents and Short-Term Investments |
| Total Debt |
| Total Liabilities |
| Stockholders Equity |
Cash Flow |
| Free Cash Flow |
| Operating Cash Flow |
| Investing Cash Flow |
| Financing Cash Flow |
Cerenome Technical Analysis
Negative
3.83
Price Trends
4.18
Negative
4.95
Negative
7.83
Negative
Market Momentum
-0.13
Negative
41.55
Neutral
38.10
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CNSY, the sentiment is Negative. The current price of 3.83 is above the 20-day moving average (MA) of 3.78, below the 50-day MA of 4.18, and below the 200-day MA of 7.83, indicating a bearish trend. The MACD of -0.13 indicates Negative momentum. The RSI at 41.55 is Neutral, neither overbought nor oversold. The STOCH value of 38.10 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for CNSY.
Cerenome Risk Analysis
Cerenome disclosed 62 risk factors in its most recent earnings report. Cerenome reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Cerenome Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
45 Neutral | $17.82M | -1.19 | -64.17% | ― | -100.00% | 82.57% | |
44 Neutral | $25.33M | >-0.01 | -198.48% | ― | -20.95% | 91.97% | |
44 Neutral | $24.14M | -0.57 | -63.87% | ― | -100.00% | 41.21% | |
44 Neutral | $13.98M | -0.25 | -503.79% | ― | ― | 82.28% | |
43 Neutral | $45.82M | -0.15 | 77.63% | ― | 6.81% | 11.95% | |
42 Neutral | $83.56M | -1.04 | -70.14% | ― | ― | 16.04% |
* Healthcare Sector Average
CNSY
Cerenome
3.68
-9.72
-72.54%
KPTI
Karyopharm Therapeutics
2.02
-3.57
-63.86%
TVRD
Tvardi Therapeutics
1.90
-22.84
-92.32%
BRNS
Barinthus Biotherapeutics
0.59
-0.60
-50.34%
SNTI
Senti Biosciences
0.45
-1.15
-71.94%
ACRV
Acrivon Therapeutics, Inc.
1.95
0.56
40.29%
Cerenome Corporate Events
Private Placements and FinancingRegulatory Filings and Compliance
Plus Therapeutics Launches New At-The-Market Equity Program
Neutral
Jun 5, 2026
On June 1, 2026, Plus Therapeutics, Inc. entered into an Equity Distribution Agreement with Canaccord Genuity LLC that allows the company to sell up to $17.35 million of its common stock in an at-the-market offering, with Canaccord acting as sales...
Executive/Board ChangesShareholder Meetings
Plus Therapeutics Stockholders Back Directors and Incentive Plan
Positive
May 15, 2026
Plus Therapeutics, Inc. held its 2026 Annual Meeting of Stockholders on May 14, 2026, with a quorum represented by 64,857,321 shares out of 171,550,698 outstanding as of the March 18, 2026 record date. Stockholders elected six directors to serve u...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.